GO
Loading...

Biogen Idec Inc

More

  • *AT&T falls after results, but Boeing rallies. *Amgen drags biotech lower, but Gilead gains. NEW YORK, April 23- U.S. stocks declined on Wednesday after a six-session winning streak as gains in Boeing and Gilead were offset by slides in AT&T and the wider biotech sector.

  • Midday Glance: Biotechnology companies Wednesday, 23 Apr 2014 | 1:37 PM ET

    Amgen Inc. fell $6.17 or 5.2 percent, to $113.13. Biogen Idec fell $5.61 or 1.8 percent, to $300.59. Celgene Corp. fell$. 59 or. 4 percent, to $146.05.

  • *AT&T falls after results, but Boeing rallies. *Amgen drags biotech lower, but Gilead gains. NEW YORK, April 23- U.S. stocks edged lower on Wednesday as weakness in AT&T and biotech names inspired investors to take profits following six straight days of gains, though a rally in Boeing limited losses.

  • Early Glance: Biotechnology companies Wednesday, 23 Apr 2014 | 10:29 AM ET

    Amgen Inc. fell $5.56 or 4.7 percent, to $113.74. Biogen Idec fell $5.05 or 1.6 percent, to $301.16. Celgene Corp. fell$. 18 or. 1 percent, to $146.46.

  • US STOCKS-Wall St edges lower following six-day S&P rally Wednesday, 23 Apr 2014 | 10:17 AM ET

    *Boeing rallies after results, outlook; AT&T drops. NEW YORK, April 23- U.S. stocks edged lower on Wednesday as strong results from Boeing failed to inspire investors to keep pushing equities higher following six straight days of gains.

  • Biogen raises forecast as 1Q profit climbs 12 pct Wednesday, 23 Apr 2014 | 9:21 AM ET

    WESTON, Mass.— Biogen Idec raised its forecast for the year as first-quarter net income increased 12 percent, helped by a revenue boost from the multiple sclerosis treatment Tysabri and a product approval. It received regulatory approval in Europe earlier this year, following approval last year from the U.S. Food and Drug Administration.

  • April 23- Biogen Idec Inc on Wednesday reported a higher first-quarter profit as sales of its new Tecfidera multiple sclerosis drug extended a run of eclipsing Wall Street sales expectations, and the U.S. biotechnology company raised its full-year forecasts.

  • April 23- Biogen Idec Inc on Wednesday reported a higher first-quarter profit as sales of its new Tecfidera multiple sclerosis drug extended its run of eclipsing Wall Street sales forecasts.

  • Final Glance: Biotechnology companies Monday, 21 Apr 2014 | 6:02 PM ET

    Amgen Inc. rose $1.56 or 1.4 percent, to $117.02. Biogen Idec rose $7.44 or 2.6 percent, to $297.98. Celgene Corp. rose $2.32 or 1.6 percent, to $143.83.

  • *Netflix climbs in extended-hours trading after results. NEW YORK, April 21- U.S. stocks advanced modestly on Monday in subdued trading as investors showed hesitation in the wake of a strong rally last week and before a slew of key earnings releases this week.

  • *Results from Netflix expected after the market close. NEW YORK, April 21- U.S. stocks advanced modestly on Monday as investors showed hesitation in the wake of a strong rally last week and ahead of key earnings releases. The S&P 500 posted its best week since July last week, boosted by results from such names as General Electric Co and Morgan Stanley.

  • Midday Glance: Biotechnology companies Monday, 21 Apr 2014 | 1:20 PM ET

    Amgen Inc. rose$. 89 or. 8 percent, to $116.35. Biogen Idec rose $3.44 or 1.2 percent, to $293.98. Celgene Corp. rose $1.03 or. 7 percent, to $142.54.

  • Can Gilead’s Sovaldi rescue biotech? Monday, 21 Apr 2014 | 12:20 PM ET
    A researcher works on a hepatitis C virus drug at Gilead Sciences lab in Foster City, Calif.

    Biotech earnings kick off Tuesday after the bell as Gilead and Amgen report. Here's what to watch for.

  • *Results from Netflix expected after the market close. NEW YORK, April 21- U.S. stocks rose slightly on Monday as investors found few reasons to push indexes sharply higher following a strong rally last week and ahead of key earnings releases.

  • US STOCKS-Wall St flat as investors await earnings Monday, 21 Apr 2014 | 10:51 AM ET

    *Results from Netflix expected after the market close. NEW YORK, April 21- U.S. stocks were flat on Monday ahead of key earnings releases as investors found few reasons to push indexes sharply higher following a strong rally last week. The S&P 500 posted its best week since July last week, boosted by results from such names as General Electric Co and Morgan Stanley.

  • Early Glance: Biotechnology companies Monday, 21 Apr 2014 | 10:31 AM ET

    Amgen Inc. rose$. 91 or. 8 percent, to $116.37. Biogen Idec rose $3.58 or 1.2 percent, to $294.12. Celgene Corp. rose $1.63 or 1.2 percent, to $143.14.

  • *Results from Netflix expected after the market close. *The S&P 500 had its best week since July last week, boosted by strong results from such names as General Electric Co and Morgan Stanley. However, thus far the earnings season has been mixed, with technology names like Google Inc and IBM struggling to impress investors.

  • April 18- Biogen Idec Inc is pricing its newly approved long-acting hemophilia drug, Alprolix, to cost U.S. patients, and insurers, about the same per year as older, less convenient therapies whose price can reach about $300,000 annually.

  • Several behemoths, including Apple, the largest U.S. company by market value, as well as Microsoft, McDonald's and AT&T, are due to report earnings.

  • The $9.4 billion Fidelity Select Biotechnology Fund plunged 11.75 percent during the first 14 days of April. That put the fund near the bottom among nearly 3,800 U.S. mutual funds tracked by Lipper Inc. Only six funds performed worse, but they had less than $100 million in assets each.

Most Popular Video

Wednesday, 23 Apr 2014 | 12:00 AM ET

Most people probably don't want their six-figure sports cars all marked up, unless it's been marked up by the world's best basketball players. This one-of-a-kind 2002 Aston Martin Vanquish is the only car on the planet to have 50 signatures on it from 50 basketball Hall of Famers, increasing its value over 500 percent.

Wednesday, 23 Apr 2014 | 1:00 PM ET

CNBC's Kelli Grant talks about the types of protection available to credit and debit card holders in the transition to a cashless society.

Wednesday, 23 Apr 2014 | 12:00 PM ET

Rumors of a delayed Apple iPhone 6 product launch and a larger display screen are swirling about the technosphere, with Lindsey Turrentine, CNET editor-in-chief.